Photodynamic diagnosis in urology: State of the art

Archivos Espanoles de Urologia

Volumn 64, Issue 1, 2011, Pages 18-31

  Cortes, Janice A Santos ^a   Gahan, Jeffrey ^a   Soloway, Mark S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Photodynamic; Phototherapy; Urothelial carcinoma

Indexed keywords

DIAGNOSTIC AGENT; PHOTOSENSITIZING AGENT;

ARTICLE; BLADDER TUMOR; COST; CYSTOSCOPY; DISEASE COURSE; DISEASE FREE SURVIVAL; ECONOMICS; HUMAN; METHODOLOGY; PHOTOCHEMOTHERAPY; STANDARD; URINARY TRACT DISEASE; UROLOGY;

COSTS AND COST ANALYSIS; CYSTOSCOPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; REFERENCE STANDARDS; URINARY BLADDER NEOPLASMS; UROLOGIC DISEASES; UROLOGY;

EID: 79551529853     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (97)

1. Jemal A, Murray T, Ward E. Cancer Statistics 2005. CA Cancer J Clin. 2005;55:10-30.
2. Messing EM, Young TB, Hunt VB, et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology. 1995b; 45:387.
3. Thorstenson A, Larsson H, Wijkstrom H, et al. Bladder cancer characteristics in a population based study of newly detected tumors. J Urol. 2003;169:864A.
4. Holmang S, Hedelin H, Anderstrom C, Holmberg E, Busch C, Johansson SL. Recurrence and progression in low grade papillary urothelial tumors. J Urol. 1999;162(3 Pt 1):702-7.
5. Kurth KH. Natural History and prognosis of untreated and treated superficial bladder cancer. In Pagano F, Fair WR eds, Superficial Bladder Cancer. Oxford: Isis Medical Media. 1997;42-56.
6. Holmang S, Hedelin H, Anderstrom C, Holmberg E, Johansson SL. The importance of the depth of invasion in stage T1 bladder carcinoma: A prospective cohort study. J Urol. 1997;157:800-4.
7. Millan-Rodriquez F, Chechile-Tomiolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol. 2000;163:73-78.
8. Soloway M, Murphy W, Rao M, Cox C. Serial multiple site biopsies in patients with bladder cancer. J Urol. 1978;120:57-59.
9. Kriegmair M, Baumgartner R, Knuchel R, Stepp H, Hofstadter F, Hofstetter A Detection of early bladder cancer by 5-aminolevulinic acid induced Porphyrin fluorescence. J Urol. 1996;155:105-110.
10. Cina SJ, Epstein JI, Endrizzi JM, Harmon WJ, Seay TM, Schoenberg MP. Correlation of cystoscopic impression with histologic diagnosis of biopsy specimens of the bladder. Hum Pathol. 2001;32:630-7.
11. Soloway MS, Bruck DS, Kim SS: Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 2003;170:438-441
12. Soloway MS: Expectant treatment of small, recurrent, low-grade, noninvasive tumors of the urinary bladder. Urol Oncol 2006;24:58-61.
13. Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol. 2006;175:1641-1644.
14. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J. EUA guidelines on non-muscle-invasive urothelial carcinomaof the bladder. Eur Urol. 2008;54:303-14.
15. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al. Guideline for the management of non muscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178:2314-2330.
16. Soloway MS, Patel J. Surgical Techniques for endoscopic resection of bladder cancer. Urol Clin North Am. 1992;19:477-71.
17. Nieder AM, Brausi M, Lamm D, et al: Management of stage T1 tumors of the bladder: International Consensus Panel. Urology. 2005;66(6 Suppl 1):108-125.
18. Herr KS, Donat SM. Quality control in transurethral resection of bladder tumours. BJU Int. 2008;102:1242-46.
19. Miladi M, Peyromaure M, Zerbib M. The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol. 2003;43:241-245.
20. Dwivedi Udai S; Kumar Abhay; Das Suren K; Trivedi Sameer; Kumar Mohan; Sunder Shyam; Singh Pratap B. Relook TURBT in superficial bladder cancer: its importance and its correlation with the tumor ploidy. Urologic Oncology. 2009;27(5):514-9.
21. Divrik T, Yildirim U, Eroglu AS, Zorlu F, Ozen H. Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer? J Urol. 2006;175:1258-61.
22. Messman H, Endlicher E, Gelbmann CM, Scholmerich J. Fluorescence endoscopy and photodynamic therapy. Digest Liver Dis. 2002;34:754-61.
23. Kelly JF, Snell ME, Berenbaum MC. Photodynamic destruction of human bladder carcinoma. Br J Cancer. 1975;31:237-244.
24. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinical useful photosensitizer for photodynamic therapy. J Photochem Photobiol. 1992;14:275-292.
25. Redmond RW, Gamlin JN. A compilation of singlet oxygen yields from biologically relevant molecules. Photochem photobiol. 1999;70:391-475.
26. Koenig F, McGovern FJ, Larne R, Enquist H, Schomacker KT, Deutsch TF. Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced by 5-aminolaevulinic acid. BJU Int. 1999;83(1):129-135.
27. Peng Q, Moan J, Warloe T, Iani V, Steen HB, Bjorseth A, Nesland JM. Build-up of esterified aminovulinic-acid-derivative-induced porphyrin fluorescence in normal mouse skin. JPhotochem photobiol. 1996;34:95-96.
28. Kloek J, Beijersbergen van Henegouwen MJ. Prodrugs of 5-aminolevulinic acid for photodynamic therapy. Photochem photobiol. 1996;64:994-1000.
29. Gaullier JM, Berg K, Peng Q, Anholt H, Selbo PK, Ma LW, et al. Use of 5-aminolaevulinic acid esters to improve photodynamic therapy on cells in culture. Cancer Res. 1997;57:1481-14.
30. Lange N, Jichlinski P, Zellweger M, Forrer M, Marti A, Guillou L, et al. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br J Cancer. 1999;80:185-93.
31. Endlicher E, Rümmele P, Hausmann F, Krieg R, Knüchel R, Rath HC, et al. Protoporphyrin IX distribution following local application of 5-aminolaevulinic acid and its esterified derivatives in the tissue layers of the normal rat colon. Br J Cancer. 2001;85:1572-1576.
32. Brunner H, Hausmann F, Krieg RC, Endlicher E, Schölmerich J, Knüchel R, et al. The effects of 5-aminolevulinic acid esters on protoporphyrin IX production in human adenocarcinoma cell lines. Photochem Photobiol. 2001;74:721-5.
33. Kubin A, Wierrani F, Burner U, Alth G, Grunberger W. Hypericin-The facts about a controversial agent. Curr Pharm Des. 2005;11:233-53.
34. Lavie G, Mazur Y, Lavie D, Meruelo D. The chemical and biological properties of hypericin - a compound with a broad spectrum of biological activities. Med Res Rev. 1995;15:111-119.
35. D'Hallewin MA, Kamuhabwa AR, Roskams T, De Witte PA, Baert L. Hypericin-based fluorescence diagnosis of bladder carcinoma. BJU Int. 2002;89:760-3.
36. Kubin A, Loew HG. Novel preparation of hypericin bonded with Poly-N-Vynilamides. European Patent EP 1 289 562 B1. (5.21. 2001).
37. Kubin A, Meissner P, Wierani F, Burner U, Bodenteich A, Pytel A, Schmeller N. Fluorescence diagnosis of bladder cancer with new water soluble hypericin bound to Polyvinylpyrrolidone: PVP-hypericin. Photochem Photobiol. 2008;84:1560-63.
38. Kriegmair M, Baumgartner R, Knuechel R, Steinbach P, Ehsan A, Lumper W, Hofstädter F, Hofstetter A. Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology. 1994;44:836-41.
39. Alken P, Siegsmund M, Gromoll-Bergmann K, Daffner P, Fenner W, Spelz J. A randomized controlled multicentre trial to compare the effects of trasurethral resection of bladder carcinomas under 5-ALA induced fluorescence light to conventional white llight.[abstract 593]. Eur Urol Suppl. 2007;6:171.
40. Zaak D, Kriegmair M, Stepp H, Baumgartner R, Oberneder R, Schneede P, Corvin S, Frimberger D, Knüchel R, Hofstetter A. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid - Results of 1012 fluorescence endoscopies, Urology. 2001;57:690-694.
41. Steinbach P, Wedmgandt H, Baumgartner R, Kriegmair M, Hofstädter F, Knüchel R. Cellular fluorescence of the endogenous photosensitiser protoporphyrin IX following exposure to 5-aminolevulinic acid. Photochem Photobiol. 1995;62:887-895.
42. Marti A, Jichlinski P, Lange N, Ballini JP, Guillou L, Leisinger HJ, Kucera P. Comparison of Aminolevulinic Acid and Hexylester Aminolevulinate Induced Protoporphyrin IX Distribution in Human Bladder Cancer. J Urol. 2003;170:428-432.
43. Burger M, Stief CG, Zaak D, Stenzl A, Wieland, WF, Jocham D, Otto W, Denzinger S. Hexaminolevulinate Is Equal to 5-Aminolevulinic Acid Concerning Residual Tumor and Recurrence Rate Following Photodynamic Diagnostic Assisted Transurethral Resection of Bladder Tumors. Urology. 2009;74:1282-1286.
44. Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C, Nseyo U, Droller MJ, PC B302/01 Study Group. A Phase III, Multicenter Comparison of Hexaminolevulinate Fluorescence Cystoscopy and White Light Cystoscopy for the Detection of Superficial Papillary Lesions in Patients With Bladder Cancer. J Urol. 2007;178:62-67. (Pubitemid 46908731)
45. Jichlinski P, Guillou L, Karlsen SJ, Malmsrtom PU, Jocham D, Brennhovd B, Johansson E, Gartner T, Lange N, et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer-a multicenter study. J Urol. 2003;170:226-229.
46. Jocham D, Witjes F, Wagner S, Zeylemaker B, van Moorselaar J, Grimm MO, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol. 2005;174:862-866.
47. Fradet Y, Grossman HB, Gomella L, Lerner S, Cookson M, Albala D, Droller MJ, PC B302/01 Study Group. A Comparison of Hexaminolevulinate Fluorescence Cystoscopy and White Light Cystoscopy for the Detection of Carcinoma In Situ in Patients With Bladder Cancer: A Phase III, Multicenter Study. J Urol. 2007;178:68-73. (Pubitemid 46908730)
48. Liu H, Wu M, Thomas YK, Lerner SP. Fluoresecence and white light cystoscopy for detecting carcinoma in situ of the bladder. J Urol. 2008;179:326.
49. Schmidbauer J, et al. "Improved Detection of Urothelial Carcinoma In Situ with Hexaminolevulinate (HAL) Florescent Cystoscopy". J Urol. 2004;171:135-138.
50. Ray ER, Chatterton K, Kahn MS, Thomas K, Chandra A, O'Brien TS. "Hexylaminolaevulinate 'Blue Light' Florescent Cystoscopy in the Investigation of Clinically Unconfirmed Positive Urine Cytology". BJU Int. 2008;103:1363-1367.
51. Kurth KH. "Natural History and Prognosis of Untreated and Treated Superficial Bladder Cancer". In Pagano F, Fair WR eds, Superficial Bladder Cancer. Oxford:Isis Medical Media, 1997:42-56.
52. Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA, et al. "Variability in the Recurrence Rate at First Follow-Up Cystoscopy After TUR In Stage TaT1 Transitional Cell Carcinoma of the Bladder: A Combined Analysis of Seven EORTC Study". Eur Euro. 2002;41:523-531.
53. Dezinger S, Burger M, Walter B, et al. Clinical relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acidinduced fluorescence diagnosis: 8-year results of prospective randomized study. Urology. 2007;69:675-79.
54. Daniltchenko DI, Riedl C, Sachs MD, Koenig F, Daha KL, Pflueger H, Loening SA, et al. Longterm benefit of 5-Aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randozimed study. J Urol. 2005;174:2129-2133.
55. Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W. Clinical relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol. 2002;168-67-71.
56. Riedl CR, Daniltchenko D, Koenig F, Simak R, Loening SA, Pflueger H. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol. 2001;165:1121-1123.
57. Stenzl AS, Roessler WR, Fradet YF, Mynderse LM, Soloway MS, Kriegmair MK, Witjes FW, Grossman HB. Hexvix fluorescence cystoscopy improves detection and resection of papillary bladder cancer and reduces early survival: a multicentre, prospective, randomized study. Eur Urol Suppl. 2009;8:373.
58. Schumacher MC, Holmäng S, Davidsson T, Friedrich B, Pedersen J, Wiklund NP. 1009 transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-ALA under visible and fluorescent light - multicenter phase III clinical trial. [abstract 1009]. Eur Urol Suppl. 2009;8:373.
59. Denzinger S, Wieland WF, Otto W, Fielbeck T, Knuechel R, Burger M. Does photodynamic transurethral resection of bladder tumor improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study. BJU Int. 2008;101:566-569.
60. Sim HG, Lau WKO, Olivo M, Tan PH, Cheng CWS. Is photodynamic diagnosis using hypericin better than white-light cystocopy for detecting superficial bladder carcinoma? BJU Int. 2005;95:1215-18.
61. D'Hallewin MA, De Witte PA, Waelkens E, Merlevede W, Baert L. Fluorescence detection of flat bladder carcinoma in situ after intravesical instillation of hypericin. J Urol. 2000;164:349-351.
62. Kriegmair M, Baumgartner R, Knuchel R, Stepp H, Hofstadter F, Hofstetter A. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol. 1996;155:105-109.
63. Tritschler S, Scharf S, Karl A, et al. Valiadation of the diagnostic value of NMP 22 BladderChek test as a marker for bladder cancer by photodynamic diagnosis. Eur Urol. 2007;51:403-408.
64. Draga RO, Grimbergen MCM, Kok ET, Jonges TN, Ruud Bosch JLH. Predictors of false positives in 5-aminolevulinic acid-induced photodynamics diagnosis of bladder carcinoma: identification of patient groups that may benefit most from highly specific optical diagnostics. Urology. 2009;74:851-856.
65. Draga RO, Grimbergen MCM, Kok ET, Jonges TN, van Swol CFP, Ruud Bosch JLH. Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after Bacillus Calmette-Guerin immunotherapy and mitomycin C intravesical therapy, Eur Urol (2009), doi: 10.10.1016/j.eururo.2009.09.037
66. Leung SCH, Lo P-C, Ng DKP, Liu W-K, Fung K-P, Fong W-P. Photodynamic activity of BAM-SiPc, an unsymmetrical bisamino silicon (IV) phthalocyanine, in tumour-bearing nude mice. Br J Pharmacol. 2008;154:1-3.
67. Josefsen LB, Boyle RW. Photodynamic therapy: novel third-generation photosensitizers one step closer? British Journal of Pharmacology. 2009;154:1-3.
68. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q. Photodynamic therapy. J Natl Cancer Inst. 1998;90:889-905. (Pubitemid 28304157)
69. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003;3:380-387.
70. Kamuhabwa AA, Di Mavungu JD, Baert L, D'Hallewin MA, Hoogmartens J, De Witte PA. Determination of hypericin in human plasma by high-performance liquid chromatography after intravesical administration in patients with transitional cell carcinoma of the bladder. Eur J Pharm Biopharm. 2005;59:469-74.
71. Klem B, Lappin G, Nicholson S, et al. Determination of the bioavailability of (14C) - hexaminolevulinate using accelerator mass spectrometry after intravesical administration to human volunteers. J Clin Pharmacol. 2006;46:456-60.
72. Brown SB, Brown EB, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol. 2004;5:497-508.
73. Nseyo UO, Dougherty TJ, Sullivan L. Photodynamic therapy in the management of resistant lower urinary tract carcinoma. Cancer. 1987;60:3113.
74. D'Hallewin MA, Baert L. Long term results of whole bladder wall photodynamic therapy for carcinoma in situ of the bladder. Urology. 1995;45:763.
75. Walther MM, Delaney TF, Smith PD, Friauf WS, Thomas GF, Shawker TH, et al. Phase I trial of photodynamic therapy in the treatment of recurrent superficial transitional cell carcinoma of the bladder. Urology. 1997;50:199.
76. Niedre MJ, Secord AJ, Patterson MS, Wilson BC. In vitro test of the validity of singlet oxygen luminescence measurements as a dose metric in photodynamic therapy. Cancer Res. 2003;63:7986.
77. Oleinick NL, Evans HH. The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat Res. 1998;150: S146.
78. Sibata CH, Colussi VC, Oleinick NL, Kinsella TJ. Photodynamic therapy in oncology. Expert Opin Pharmacother. 2001;2:917-927.
79. Uchibayashi T, Koshida K, Kunimi K, Hisazumi H. Whole bladder photodynamic therapy for refractory carcinoma in situ of the bladder. Br J Cancer. 1995;71:625.
80. Berger AP, Steiner H, Stenzl A, Akkad T, Bartsch G, Holtl L. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer, a single-center study. Urology. 2003;61:338-341.
81. Manyak MJ, Ogan K. Photodynamic therapy for refractory superficial bladder cancer: long-term clinical outcomes of single treatment using intravesical diffusion medium. J Endourol. 2003;17:633.
82. Nseyo UO, DeHaven J, Dougherty TJ, Potter WR, Merrill DL, Lundahl SL, et al. Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience. J Clin Laser Med Surg. 1998;16:61.
83. Shackley DC, Briggs C, Gilhooley A, Whitehurst C, O'Flynn KJ, Betts CD, et al. Photodynamic therapy for superficial bladder cancer under local anaesthetic. BJU Int. 2002;89:665.
84. French AJ, Datta SN, Allman R, Matthews PN. Investigation of sequential mitomycin C and photodynamic therapy in a mitomycin-resistant bladder cancer cell-line model. BJU Int. 2004;93:156.
85. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol. 2001;13:506-513.
86. Bhuvaneswari R, Gan YY, Soo KC, Olivo M. Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Molecular Cancer. 2009;8:94.
87. Bottesman M, et al. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21:1315-1330.
88. Avritscher E, et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology. 2006;68:549-553.
89. Hedelin H, Holmang S, Wiman L. The cost of bladder tumour treatment and follow-up. Scand J Urol Nephrol. 2002;36:344-347.
90. Sangar VK, Ragavan N, Matanhelia SS, et al. The economic consequences of prostate and bladder cancer in the UK. BJU Int. 2005;95:59-63.
91. Stenzl A, et al. Fluorescence assisted transurethral resection of bladder tumours: is it cost effective? Eur Urol. 2001;39:31.
92. Burger M, Zaak D, Stief CG, Filbeck T, Wieland WF, Roessler W, Dezinger S. Photodynamic diagnostics and noninvasive bladder cancer: is it costeffective in long term-application? A Germanybased cost analysis. Eur Urol. 2007;52:142-147.
93. Zaak D, Wieland WF, Stief CG, Burger M. Routine use of photodynamic diagnosis of bladder cancer. Pract Econ Issues. Eur Urol Suppl. 2008;7: S536-541.
94. Dindyal S, Nitkunan Y, Bunce CJ. The economic benefit of photodynamic diagnosis in non-muscle invasive bladder cancer. Photodiagnosis Photodyn Ther. 2009;5:153-158.
95. Malmstrom PU, Hedelin H. Potential cost savings through the use of fluorescence cystoscopy in superficial bladder cancer: development of an economic model. Urology. 2006;68: S40-41.
96. Penkoff H, Steiner H, Dajc-Sommerer E, et al. Transurethral detection and resection of bladder carcinomas under white or 5-ALA induced fluorescence light: results of the first double-blind placebo-controlled clinical trial. Abstract no. 1085 presented at the annual American Urological Association congress, May 19-24, 2007, Anaheim, CA.
97. Kausch I, Sommerauer M, Montorsi F, Stenzl A, Jacqmin D, Jichlinski P, et al. Photodynamic Diagnosis in Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Cumulative Analysis of Prospective Studies. Eur Urol. 2010;57:595-606.